このページの翻訳は実験的なもので、現在開発中です。お待ちしております

C-MER Medical Holdings マネジメント

マネジメント基準チェック /24

現在、CEO に関する十分な情報がありません。

主要情報

Dennis Lam

最高経営責任者

HK$6.0m

報酬総額

CEO給与比率	95.7%
CEO在任期間	no data
CEOの所有権	0.9%
経営陣の平均在職期間	データなし
取締役会の平均在任期間	5.3yrs

経営陣の近況

Recent updates

CEO報酬分析

C-MER Medical Holdings の収益と比較して、Dennis Lam の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Jun 30 2024	n/a	n/a	HK$63m
Mar 31 2024	n/a	n/a	HK$63m
Dec 31 2023	HK$6m	HK$6m	HK$62m
Sep 30 2023	n/a	n/a	HK$28m
Jun 30 2023	n/a	n/a	-HK$7m
Mar 31 2023	n/a	n/a	-HK$14m
Dec 31 2022	HK$6m	HK$6m	-HK$22m
Sep 30 2022	n/a	n/a	HK$545k
Jun 30 2022	n/a	n/a	HK$23m
Mar 31 2022	n/a	n/a	HK$22m
Dec 31 2021	HK$6m	HK$6m	HK$22m
Sep 30 2021	n/a	n/a	HK$25m
Jun 30 2021	n/a	n/a	HK$28m
Mar 31 2021	n/a	n/a	HK$11m
Dec 31 2020	HK$4m	HK$4m	-HK$6m
Sep 30 2020	n/a	n/a	-HK$10m
Jun 30 2020	n/a	n/a	-HK$13m
Mar 31 2020	n/a	n/a	HK$14m
Dec 31 2019	HK$1m	HK$1m	HK$41m
Sep 30 2019	n/a	n/a	HK$53m
Jun 30 2019	n/a	n/a	HK$64m
Mar 31 2019	n/a	n/a	HK$53m
Dec 31 2018	HK$1m	HK$1m	HK$43m
Sep 30 2018	n/a	n/a	HK$35m
Jun 30 2018	n/a	n/a	HK$27m
Mar 31 2018	n/a	n/a	HK$31m
Dec 31 2017	HK$4m	HK$3m	HK$40m

報酬と市場: Dennisの総報酬 ($USD 770.74K ) は、 Hong Kong市場 ($USD 380.00K ) の同規模の企業の平均を上回っています。

報酬と収益: Dennisの報酬は、過去 1 年間の会社の業績と一致しています。

CEO（最高経営責任者

Dennis Lam (64 yo)

no data

在職期間

HK$6,018,000

報酬

Dr. Shun Chiu Lam, JP, also known as Dennis, serves as Chairman and Chief Executive Officer of C-MER Medical Holdings Limited (formerly known as C-MER Eye Care Holdings Limited). Dr. Lam is also a director...

取締役

名称	ポジション	在職期間	報酬	所有権
Shun Chiu Lam	Chairman & CEO	no data	HK$6.02m	0.93% HK$ 27.9m
Xiaoting Li	Executive Director	7.3yrs	HK$3.81m	データなし
Yau Wing Lee	Head of Hong Kong Operation & Executive Director	7.3yrs	HK$240.00k	1.06% HK$ 31.8m
Chiu Cheung Ma	Independent Non-Executive Director	6.8yrs	HK$240.00k	データなし
Pak-kuen Auyeung	Independent Vice Chairman of the Board	3.8yrs	HK$759.00k	0.024% HK$ 722.4k
Ke Yin	Independent Non-Executive Director	1.2yrs	HK$120.00k	データなし
Shu Kwan Ip	Independent Non-Executive Director	3.8yrs	HK$240.00k	データなし

5.3yrs

平均在職期間

64yo

平均年齢

経験豊富なボード: 3309の取締役会は経験豊富であると考えられます ( 5年の平均在任期間)。

C-MER Medical Holdings マネジメント

マネジメント 基準チェック /24

主要情報

経営陣の近況

Chairman & CEO recently bought HK$776k worth of stock

Chairman & CEO recently bought HK$841k worth of stock

C-MER Eye Care Holdings Limited, Annual General Meeting, May 28, 2024

C-MER Eye Care Holdings Limited Announces Board Changes, Effective July 3, 2023

Insufficient new directors

Insufficient new directors

Recent updates

Chairman & CEO recently bought HK$776k worth of stock

Investor sentiment deteriorates as stock falls 21%

First half 2024 earnings released: EPS: HK$0.025 (vs HK$0.024 in 1H 2023)

C-MER Medical Holdings Limited to Report First Half, 2024 Results on Aug 29, 2024

Chairman & CEO recently bought HK$841k worth of stock

C-MER Eye Care Holdings Limited, Annual General Meeting, May 28, 2024

New major risk - Revenue and earnings growth

C-MER Eye Care Holdings Limited to Report Fiscal Year 2023 Results on Mar 26, 2024

First half 2023 earnings released: EPS: HK$0.024 (vs HK$0.012 in 1H 2022)

C-MER Eye Care Holdings Limited Provides Earnings Guidance for the Six Months Ended 30 June 2023

C-MER Eye Care Holdings Limited to Report First Half, 2023 Results on Aug 30, 2023

C-MER Eye Care Holdings Limited Announces Board Changes, Effective July 3, 2023

Insufficient new directors

Now 22% undervalued after recent price drop

Full year 2022 earnings released: HK$0.018 loss per share (vs HK$0.019 profit in FY 2021)

Now 22% undervalued

Insufficient new directors

Chairman & CEO recently bought HK$1.9m worth of stock

Chairman & CEO recently bought HK$1.3m worth of stock

Insufficient new directors

First half 2022 earnings released: EPS: HK$0.012 (vs HK$0.012 in 1H 2021)

Insufficient new directors

C-MER Eye Care Holdings Limited to Report First Half, 2022 Results on Aug 30, 2022

Full year 2021 earnings released: EPS: HK$0.019 (vs HK$0.006 loss in FY 2020)

C-MER Eye Care Holdings Limited, Annual General Meeting, May 24, 2022

C-MER Eye Care Holdings Limited Recommends No Payment of Any Final Dividend for the Year Ended 31 December 2021

C-MER Eye Care Holdings Limited (SEHK:3309) entered into the Sale and Purchase agreements to acquire Champion Eye Centre Limited from Yeung, Hung, Pauline Chan, Ko, DN Chan,Yip, and the Estate of Cheung for HKD 56.02 million.

C-MER Eye Care Holdings Limited (SEHK:3309) entered into an Equity Transfer Agreement to acquire 7% stake in Shenzhen Aikangjian Group Co., Ltd. from Shenzhen Capital Group Co., Ltd. for CNY 45.5 million

First half 2021 earnings released: EPS HK$0.012 (vs HK$0.02 loss in 1H 2020)

C-MER Eye Care Holdings Limited Provides Unaudited Consolidated Earnings Guidance for the Six Months Ended June 30, 2021

Independent Non-Executive Director recently bought HK$1.6m worth of stock

C-MER Eye Care Holdings Limited Approves Final Dividend for the Year Ended 31 December 2020

Upcoming dividend of HK$0.02 per share

Full year 2020 earnings released: HK$0.006 loss per share (vs HK$0.04 profit in FY 2019)

Full year 2020 earnings released: HK$0.006 loss per share (vs HK$0.04 profit in FY 2019)

C-MER Eye Care Holdings Limited to Report Fiscal Year 2020 Results on Mar 31, 2021

New 90-day high: HK$6.89

C-MER Eye Care Holdings Limited (SEHK:3309) signed a Purchase Agreement to acquire 60% stake in CAD/CAM Restorative Dental Centre Limited from YIU Bun Ka for HK$12.9 million.

New 90-day high: HK$6.44

Independent Non-Executive Director recently bought HK$1.8m worth of stock

C-MER Eye Care Holdings Limited Announces Board Changes

New 90-day low: HK$5.58

Independent Non-Executive Director recently bought HK$208k worth of stock

New 90-day low: HK$5.86

First half earnings released

Independent Non-Executive Director recently bought HK$138k worth of stock

Independent Non-Executive Director recently bought HK$130k worth of stock

First half earnings released

C-MER Eye Care Holdings Limited to Report First Half, 2020 Results on Aug 28, 2020

CEO報酬分析

CEO（最高経営責任者

在職期間

報酬

取締役

平均在職期間

平均年齢

マネジメント基準チェック /24